Androgen Hormonal Suppression and Radiation — Competitive Intelligence Brief

Androgen Hormonal Suppression and Radiation (Androgen Hormonal Suppression and Radiation) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen deprivation therapy (combination with radiation). Area: Oncology.

phase 3 Androgen deprivation therapy (combination with radiation) Androgen receptor pathway Oncology Small molecule

Target snapshot

Androgen Hormonal Suppression and Radiation (Androgen Hormonal Suppression and Radiation) — Dana-Farber Cancer Institute. This combination therapy suppresses androgen signaling in prostate cancer cells while using radiation to directly damage tumor DNA and kill cancer cells.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Androgen Hormonal Suppression and Radiation TARGET	Androgen Hormonal Suppression and Radiation	Dana-Farber Cancer Institute	phase 3	Androgen deprivation therapy (combination with radiation)	Androgen receptor pathway
Androgen Suppression Therapy	Androgen Suppression Therapy	Proton Collaborative Group	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor pathway / testosterone / DHT
Cabazitaxel + Androgen deprivation therapy	Cabazitaxel + Androgen deprivation therapy	Örebro University, Sweden	phase 3	Taxane chemotherapy + Androgen deprivation therapy	Microtubules (cabazitaxel); androgen receptor pathway (ADT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen deprivation therapy (combination with radiation) class)

1. Dana-Farber Cancer Institute · 1 drug in this class